Literature DB >> 6725950

Passive immunization against murine malaria with an IgG3 monoclonal antibody.

W R Majarian, T M Daly, W P Weidanz, C A Long.   

Abstract

Spleen cells of BALB/c mice that were immune to the 17X strain of P. yoelii were fused with P3X63Ag8 myeloma cells. Two hundred fifty-three of 1053 hybrid cells produced antibodies reactive with disrupted 17X parasites in a solid phase radioimmunoassay. One of these antibodies, McAb 302, reacted with the merozoites of the 17X (nonlethal) and 17XL (lethal) variants of P. yoelii. Of greater significance, McAb 302 passively protected mice against challenge infection with the lethal variant. Mice treated with this antibody before infection developed low-grade parasitemia (less than 0.3%) of short duration when challenged with P. yoelii 17XL . In contrast, control mice that had been untreated or injected with ascites fluid lacking McAb 302 uniformly died with fulminating malaria upon challenge with the same parasite. In other experiments, McAb 302 was shown capable of controlling blood parasite levels when administered to mice with patent P. yoelii 17XL infections. Although all control mice died, mice protected with a single dose of McAb 302 ultimately cleared their infections. Regardless of how passive immunization was performed, mice given McAb 302 were resistant to subsequent challenge with P. yoelii 17XL , indicating they had developed significant immunity during their initial controlled infections. McAb 302 also showed pronounced passive protective activity against the nonlethal 17X strain of P. yoelii, which is a parasite of reticulocytes. The protection afforded by McAb 302 was specific, because mice passively immunized with this antibody died when challenged with the unrelated P. vinckei. McAb 302 was shown to possess the IgG3 isotype and precipitated a 230-kd protein plus several smaller polypeptides from metabolically labeled parasite antigen preparation derived from both variants of P. yoelii. It did not react with similar preparations of other murine plasmodial species.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6725950

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  59 in total

1.  Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection.

Authors:  T M Daly; C A Long
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

2.  Roles of conserved and allelic regions of the major merozoite surface protein (gp195) in immunity against Plasmodium falciparum.

Authors:  G S Hui; A Hashimoto; S P Chang
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

3.  Genome-wide expression profiling in malaria infection reveals transcriptional changes associated with lethal and nonlethal outcomes.

Authors:  Kurt Schaecher; Sanjai Kumar; Anjali Yadava; Maryanne Vahey; Christian F Ockenhouse
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

Review 4.  Where are we in the quest for vaccines for malaria?

Authors:  W A Siddiqui
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

5.  Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Vietnam.

Authors:  E Elsa Herdiana Murhandarwati; Lina Wang; Casilda G Black; Doan Hanh Nhan; Thomas L Richie; Ross L Coppel
Journal:  Infect Immun       Date:  2009-07-20       Impact factor: 3.441

6.  Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant.

Authors:  C Yang; W E Collins; J S Sullivan; D C Kaslow; L Xiao; A A Lal
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

7.  Advances and challenges in malaria vaccine development.

Authors:  Ruobing Wang; Joseph D Smith; Stefan H I Kappe
Journal:  Expert Rev Mol Med       Date:  2009-12-16       Impact factor: 5.600

8.  Cytokine and antibody production during the course of resolution in Plasmodium yoelii 17XL-infected BALB/c mice treated with febrifugine and isofebrifugine mixture from leaves of Hydrangea macrophylla var. Otaksa.

Authors:  A Ishih; T Nagata; F Kobayashi; T Miyase; M Terada
Journal:  Parasitol Res       Date:  2004-08-26       Impact factor: 2.289

9.  Studies of murine malaria antigens using monoclonal antibodies. Production, selection, and characterization of antibodies.

Authors:  G Holmquist; P Borwell; A R Cattan; H Wigzell
Journal:  Z Parasitenkd       Date:  1986

10.  Generalized immunological recognition of the major merozoite surface antigen (gp195) of Plasmodium falciparum.

Authors:  S P Chang; G S Hui; A Kato; W A Siddiqui
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.